David Risinger
Stock Analyst at Leerink Partners
(3.37)
# 388
Out of 5,218 analysts
193
Total ratings
60.76%
Success rate
44.83%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AbbVie | Upgrades: Outperform | 206 | 173.5 | 18.73% | 7 | Nov 22, 2024 | |
Bristol-Myers Squibb | Upgrades: Outperform | 55 73 | 55.73 | 30.99% | 4 | Nov 12, 2024 | |
Tectonic Therapeutic | Maintains: Outperform | 49 69 | 45.42 | 51.92% | 2 | Nov 11, 2024 | |
Tenax Therapeutics | Initiates Coverage On: Outperform | 16 | 5.83 | 174.44% | 1 | Oct 24, 2024 | |
Regeneron Pharmaceut... | Downgrades: Market Perform | 1175 1077 | 730.7 | 47.39% | 7 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 44 | n/a | n/a | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 106 153 | 87.74 | 74.38% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 15 10 | 9.87 | 1.32% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 28 2 | 1.97 | 1.52% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 47 | 15.6 | 201.28% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 267 318 | 270.45 | 17.58% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 11 | 16.58 | -33.66% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 410 458 | 789.07 | -41.96% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 42 | 47.98 | -12.46% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 374 365 | 463.5 | -21.25% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 81 91 | 91.85 | -0.93% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 49 48 | 25.59 | 87.57% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 194 186 | 146.69 | 26.8% | 2 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 8 10 | 11.83 | -15.47% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 88 117 | n/a | n/a | 12 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 10 | 17.49 | -42.82% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 35 37 | 15.32 | 141.51% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 162 176 | 123 | 43.09% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 16 | 12.63 | 26.68% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 53 45 | 27.42 | 64.11% | 7 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 5 7 | n/a | n/a | 8 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 22 35 | 7.78 | 349.87% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 41 | 12.12 | 238.28% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 167 174 | 178.34 | -2.43% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 51 | 24.84 | 105.31% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 8 | 16.48 | -51.46% | 14 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 18 | n/a | n/a | 12 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 89 | 102.09 | -12.82% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 16 | 30.46 | -47.47% | 6 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 7.83 | -61.69% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 156 | n/a | n/a | 8 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 14 35 | n/a | n/a | 5 | Aug 17, 2018 |